stockportfolio.pro
Stryker Corporation (SYK)
Healthcare · Medical Devices · NYSE
Stryker Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.32B | $12.44B | $13.60B | $14.88B | $14.35B | $17.11B | $18.45B | $20.50B | $22.59B | $25.12B |
| Gross profit | $7.50B | $8.18B | $8.94B | $9.70B | $9.06B | $10.97B | $11.58B | $13.06B | $14.44B | $16.07B |
| Net income | $1.65B | $1.02B | $3.55B | $2.08B | $1.60B | $1.99B | $2.36B | $3.17B | $2.99B | $3.25B |
| Net margin | 14.5% | 8.2% | 26.1% | 14.0% | 11.1% | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
Source: Stryker Corporation SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into SYK stock?
At today's market cap of $120.38B, Stryker Corporation is priced for free-cash-flow growth of about 12.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $4.28B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 9%/yr over the last five fiscal years and revenue 11.8%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Stryker Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SYK in your portfolio →
Stryker Corporation financial history by metric
About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Stryker Corporation — frequently asked questions
What is Stryker Corporation's revenue?
Stryker Corporation (SYK) reported revenue of $25.12B for fiscal year 2025, up 11.2% from the prior year, according to its SEC filings.
Is Stryker Corporation profitable?
Yes. SYK earned net income of $3.25B in fiscal 2025, a net margin of 12.9%.
What is SYK's P/E ratio?
Stryker Corporation trades at a price-to-earnings ratio of about 36.3 based on the latest data in our nightly-refreshed cache.
How fast is Stryker Corporation growing?
SYK's revenue grew at roughly 11.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Stryker Corporation have?
As of fiscal year 2025, SYK carried roughly $15.86B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Stryker Corporation's gross margin?
SYK's gross margin was 64.0% in fiscal 2025 — gross profit of $16.07B on revenue of $25.12B.
What is Stryker Corporation's market cap?
Stryker Corporation (SYK) has a market capitalization of about $120.38B, based on the latest data in our nightly-refreshed cache.
When does Stryker Corporation's fiscal year end?
SYK's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into SYK stock?
At today's market cap of $120.38B, Stryker Corporation is priced for free-cash-flow growth of about 12.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $4.28B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 9%/yr over the last five fiscal years and revenue 11.8%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Stryker Corporation's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.